Even A Likely FDA Approval For A Rare Disorder May Not Meaningfully Move The Needle For This Biotech Stock

A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.

FDA approves pill which can prevent heart attack, stroke by reducing inflammation: How it works

The FDA has approved Rybelsus, the first oral GLP-1 receptor agonist, for managing cardiovascular risks in adults. This ...

Semaglutide showdown: Pills or shots—Which is right for you?

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

Is a new non-hormonal pill the answer to hot flashes in menopausal women?

The US Food and Drug Administration has approved a drug that could ease menopausal hot flashes and night sweats. Developed by ...

What are some safe Ozempic alternatives for weight loss?

This article was reviewed by Darragh O’Carroll, MD. Ozempic Alternatives for Weight Loss Key takeaways: Ozempic® alternatives ...
Zacks.com on MSN

NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients

Novo Nordisk secures FDA approval for Rybelsus as the first oral GLP-1 therapy proven to cut major heart risks in adults with type II diabetes.

Ionis: What Upside Is Left After Shares Rocketed Higher Following Positive Trial Data?

Ionis Pharmaceuticals, Inc. shows promise with new drug launches and a robust pipeline. Click here to read IONS stock ...

Why Russian Teenagers Are Obsessed With Molecule, A Controversial Weight Loss Pill

Molecule is claimed to be made from "natural ingredients" such as dandelion root and fennel seed, but investigations tell a ...

Does America's New Favorite Anxiety Drug Have a Dark Side?

Gabapentin has become the 5th most prescribed drug. It's also getting a bad reputation. Here's why it doesn't deserve it, ...
Pharmabiz

Novo Nordisk's Rybelsus gets US FDA approval for CV risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event

Novo Nordisk's Rybelsus gets US FDA approval for CV risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event: Plainsbo ...

FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a ...

Rybelsus® (semaglutide) tablets 7 mg or 14 mg, the only FDA-approved oral GLP-1 medicine available, now indicated to reduce the risk of major adverse cardiovascular events ...